SCHEMBL5395271

SCHEMBL5395271

CC(C)Cn1c(=O)n(C)c(=O)c2c(-c3ncc[nH]3)n(Cc3cccc4ccccc34)nc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A1 P53985 3/20 0.49
PDE5A O76074 6/20 0.43
PDE3B Q13370 2/20 0.43
PDE3A Q14432 2/20 0.43
CYP2C9 P11712 1/20 0.43
MAPKAPK2 P49137 1/20 0.43
CAMK2B Q13554 1/20 0.43
HIPK4 Q8NE63 1/20 0.43
ALDH1A1 P00352 3/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE1A P54750 2/20 0.39
PDE1B Q01064 2/20 0.39
PDE1C Q14123 2/20 0.39
PDE2A O00408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5400640 0.86 SLC16A1 (0.54) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5395371 0.85 SLC16A1 (0.52) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5400603 0.84 SLC16A1 (0.52) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5407601 0.84 SLC16A1 (0.49) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5405834 0.83 SLC16A1 (0.49) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5397712 0.83 SLC16A1 (0.49) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5399495 0.82 SLC16A1 (0.53) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5405616 0.82 SLC16A1 (0.51) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5402601 0.82 SLC16A1 (0.53) SLC16A1PDE5APDE3BPDE3ACYP2C9
SCHEMBL5399735 0.82 SLC16A1 (0.51) SLC16A1PDE5APDE3BPDE3ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC SLC16A1 4140/4885PDE5A 933/4885PDE3B 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.